Safety of Advanced Combination Treatment With Selective JAK1 Inhibitors and Biological Therapies in Inflammatory Bowel Diseases: A Real World Experience
Alimentary Pharmacology & Therapeutics · 2025
DOI: 10.1111/apt.70077 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Alimentary Pharmacology & Therapeutics, 2025. Verfasst von Cécile Cussac und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Pancreatology, Hôpital Rangueil, CHU de Toulouse, Université Toulouse Paul Sabatier, Toulouse, France. Hauptthemen laut MEDLINE: Inflammatory Bowel Diseases, Janus Kinase 1, Janus Kinase Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
This multicenter retrospective study examines 18 patients with difficult‐to‐treat inflammatory bowel diseases who received advanced combination treatment (ACT) with selective JAK1 inhibitors and biologics, totaling 11.8 patient‐years of exposure. Treatment was discontinued in three patients due to adverse events. At 3 months, 77.8% achieved steroid‐free clinical remission. The infection incidence rate was 25.4 per 100 person‐years (95% CI: 6.47–69.19), though the wide confidence interval limits conclusions on safety differences with monotherapy. These findings highlight the importance of preventive measures, careful patient selection, and rigorous monitoring to mitigate infection risks associated with ACT.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology and Pancreatology, Hôpital Rangueil, CHU de Toulouse, Université Toulouse Paul Sabatier, Toulouse, France.
- Department of Gastroenterology and Hepatology, Centre Médico-Chirurgical Magellan, Hôpital Haut-Lévêque, CHU de Bordeaux, Bordeaux, France.
- Université de Bordeaux; INSERM CIC 1401, Bordeaux, France.
- Department of Hepato-Gastroenterology, Hôpital Saint-Eloi, CHU Montpellier, Université de Montpellier, Montpellier, France.
- Department of Gastroenterology, Nimes University Hospital, Nimes, France.
ORCID-Profile: Pauline Rivière, Romain Altwegg, David Laharie
Zitieren
APA
Cussac, C., Rivière, P., Altwegg, R., Caillo, L., Poullenot, F., Laharie, D., Gilletta, C., & Le Cosquer, G. (2025). Safety of Advanced Combination Treatment With Selective JAK1 Inhibitors and Biological Therapies in Inflammatory Bowel Diseases: A Real World Experience. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.70077
Vancouver
Cussac C, Rivière P, Altwegg R, Caillo L, Poullenot F, Laharie D, et al. Safety of Advanced Combination Treatment With Selective JAK1 Inhibitors and Biological Therapies in Inflammatory Bowel Diseases: A Real World Experience. Alimentary Pharmacology & Therapeutics. 2025. doi:10.1111/apt.70077
BibTeX
@article{Cussac2025,
author = {Cussac, Cécile and Rivière, Pauline and Altwegg, Romain and Caillo, Ludovic and Poullenot, Florian and Laharie, David and Gilletta, Cyrielle and Le Cosquer, Guillaume},
title = {Safety of Advanced Combination Treatment With Selective JAK1 Inhibitors and Biological Therapies in Inflammatory Bowel Diseases: A Real World Experience},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2025},
doi = {10.1111/apt.70077}
}
EUVIMED